Aripiprazole

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.